Igniting the path from multi-omics to precision medicine.
Igniting the path from multi-omics to precision medicine.
Igniting the path from multi-omics to precision medicine.
Omics At Scale
Next-generation omics tools, like proteomics, are now routinely conducted at population scale - unlocking a new pipeline of potential diagnostics & therapeutics.
Next-generation omics tools, like proteomics, are now routinely conducted at population scale - unlocking a new pipeline of potential diagnostics & therapeutics.
Next-generation omics tools, like proteomics, are now routinely conducted at population scale - unlocking a new pipeline of potential diagnostics & therapeutics.
0
0
samples profiled in UK Biobank
via the Pharma Proteomics Project
0
0
samples profiled in UK Biobank
via the Pharma Proteomics Project
0+
0+
samples profiled in other cohorts
e.g., Finngen, AllofUs, GNPC
0+
0+
samples profiled in other cohorts
across selected Finnish biobanks
0+
0+
samples profiled in other cohorts
e.g., Finngen, AllofUs, GNPC
0+
0+
samples profiled by 2027
in UKB and other open-access cohorts
0+
0+
samples profiled by 2027
in UKB and other open-access cohorts
This shift has fueled thousands of peer-reviewed papers, revealed hundreds of novel biomarker candidates, and reshaped the early portfolios of 30+ global drug companies.
This shift has fueled thousands of peer-reviewed papers, revealed hundreds of novel biomarker candidates, and reshaped the early portfolios of 30+ global drug companies.
This shift has fueled thousands of peer-reviewed papers, revealed hundreds of novel biomarker candidates, and reshaped the early portfolios of 30+ global drug companies.
Immediate R&D impact
0+
0+
papers citing the UKB-PPP dataset
since November 2023
0+
0+
papers citing the UKB-PPP dataset
since November 2023
0+
0+
potential new drug targets
found so far - i.e., proteins with robust disease links, not already drugged
0+
0+
potential new drug targets
0+
0+
potential new drug targets
found so far - i.e., proteins with robust disease links, not already drugged
~0
~0
new biomarker candidates
described to date - i.e., proteins linked to the onset of 70+ different illnesses
~0
~0
new biomarker candidates
described to date - i.e., proteins linked to the onset of 70+ different illnesses
From BreakthroughS to BottlenecKS
Despite this progress, transforming insights from population omics studies into CLIA-ready tests still takes 3-5 years and~$30 million, while developing new drugs takes 10-15 years and >$1 billion.
Despite this progress, transforming insights from population omics studies into CLIA-ready tests still takes 3-5 years and~$30 million, while developing new drugs takes 10-15 years and >$1 billion.
Despite this progress, transforming insights from population omics studies into CLIA-ready tests still takes 3-5 years and~$30 million, while developing new drugs takes 10-15 years and >$1 billion.
Our Solution
Our Solution
Igniting impact through population omics.
Igniting impact through population omics.
Igniting population health impact.
Ignition Scientific bridges the gap between population-scale omics studies and real-world healthcare impact. We help optimize next-generation technologies, enhance promising cohorts and biobanks, and connect biotechs, nonprofits, academics & regulators to accelerate the path from discovery to adoption.
Ignition Scientific bridges the gap between population-scale omics studies and real-world healthcare impact. We help optimize next-generation technologies, enhance promising cohorts and biobanks, and connect biotechs, nonprofits, academics & regulators to accelerate the path from discovery to adoption.
Ignition Scientific bridges the gap between population-scale omics studies and real-world healthcare impact. We help optimize next-generation technologies, enhance promising cohorts and biobanks, and connect biotechs, nonprofits, academics & regulators to accelerate the path from discovery to adoption.
Build
Apps & decision-making tools
Ignition builds and maintains open resources for the research community, such as the Atlas of Proteomic Technologies, which benchmarks next-generation commercial proteomics platforms and helps guide scientists towards the most appropriate assay for their study.
Advise
Independent, evidence-based consultation
Because we build the benchmarks ourselves, our guidance on platform choice, study design, and target prioritization is evidence-led. We work with academic teams, foundations, and biotechs to make the calls that de-risk what comes next.
Connect
Consortium formation & scientific collaboration
A promising drug target or biomarker only matters if researchers, platforms, and funders move in the same direction. Ignition sits at this intersection - translating between them so a candidate becomes a fundable diagnostic or therapeutic program.
Build
Apps & decision-making tools
Ignition builds and maintains open resources for the research community, such as the Atlas of Proteomic Technologies, which benchmarks next-generation commercial proteomics platforms and helps guide scientists towards the most appropriate assay for their study.
Advise
Independent, evidence-based consultation
Because we build the benchmarks ourselves, our guidance on platform choice, study design, and target prioritization is evidence-led. We work with academic teams, foundations, and biotechs to make the calls that de-risk what comes next.
Connect
Consortium formation & scientific collaboration
A promising drug target or biomarker only matters if researchers, platforms, and funders move in the same direction. Ignition sits at this intersection - translating between them so a candidate becomes a fundable diagnostic or therapeutic program.
WHO ARE WE?
WHO ARE WE?
Ignition Scientific was founded by Chris Whelan, Ph.D., the founding chair of the UK Biobank Pharma Proteomics Project (UKB-PPP). After nearly a decade in pharma translating large-scale molecular datasets into therapeutic targets and biomarkers, Chris launched Ignition to work more closely with nonprofits, academics and start-ups, bringing population biobanks and multi-omics studies closer to real-world impact.
Ignition Scientific was founded by Chris Whelan, Ph.D., the founding chair of the UK Biobank Pharma Proteomics Project (UKB-PPP). After nearly a decade in pharma translating large-scale molecular datasets into therapeutic targets and biomarkers, Chris launched Ignition to work more closely with nonprofits, academics and start-ups, bringing population biobanks and multi-omics studies closer to real-world impact.
How We Work
How We Work
Work with Ignition
Work with Ignition
Work with Ignition
We collaborate with academic teams, foundations, and early-stage biotechs to turn promising molecular signals into translational programs. Whether you’re refining a technology, designing a study, advancing IP, or preparing for early clinical validation, Ignition offers hands-on collaboration at various stages of development.
We collaborate with academic teams, foundations, and early-stage biotechs to turn promising molecular signals into translational programs. Whether you’re refining a technology, designing a study, advancing IP, or preparing for early clinical validation, Ignition offers hands-on collaboration at various stages of development.
1
Advisory
Strategic guidance on proteomic study design, data interpretation, and/or technology optimization.
We work with academic teams, foundations, and startups to advance their multi-omics strategy - from biomarker discovery and study design to data interpretation and technology assessment.
1
Advisory
Strategic guidance on proteomic study design, data interpretation, and/or technology optimization.
We work with academic teams, foundations, and startups to advance their multi-omics strategy - from biomarker discovery and study design to data interpretation and technology assessment.
Advisory
Strategic guidance on proteomic study design, data interpretation, and/or technology optimization.
We work with academic teams, foundations, and startups to advance their multi-omics strategy - from biomarker discovery and study design to data interpretation and technology assessment.
2
Incubation
Co-developing IP and translational plans
For promising molecular signals, we act as hands-on collaborators - refining hypotheses, developing IP, and charting paths toward validation and commercialization.
2
Incubation
Co-developing IP and translational plans
For promising molecular signals, we act as hands-on collaborators - refining hypotheses, developing IP, and charting paths toward validation and commercialization.
Incubation
Co-developing IP and translational plans
For promising molecular signals, we act as hands-on collaborators - refining hypotheses, developing IP, and charting paths toward validation and commercialization.
3
Translation
Bridging promising ideas with capital and clinical partners
We support the path from robust signal to diagnostic and therapeutic company formations — connecting partners with enabling platforms, funding networks, and potential spinout partners.
Translation
Bridging promising ideas with capital and clinical partners
We support the path from robust signal to diagnostic and therapeutic company formations — connecting partners with enabling platforms, funding networks, and potential spinout partners.
